Komori
Zeria Pharmaceutical (4559) · InitiativeAdvanced

Strengthening Internal Controls and Group Company Management

First written in FY2016. 2 of 5 entries say "Restated". Latest entry: FY2024.

5entries
9years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2016 – FY2019AdvancedFY2023 – FY20242016: 120162017: 120172018: 020182019: 120192020: 020202021: 020212022: 020222023: 120232024: 12024
Same theme, other companies
Internal Controls and Business Execution Monitoring Framework for SubsidiariesA theme 330 companies write about · 17 as a headwind · 317 as a tailwind

41 other companies' latest entry also says "Advanced".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 198 companies compared. The sentences above are computed from all 198.Comparing 200 of the theme's 336 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2024AdvancedAnnual report

    「Most recently, in April 2024, we revised the standards to reflect current laws, regulatory changes and the company’s circumstances, and are working to ensure their full implementation through training and other activities at operating sites.」

    The Zeria Group Compliance Standards were revised in April 2024, followed by efforts to ensure awareness and thorough implementation through training.
  2. FY2023AdvancedAnnual report

    「To comply with the amended Whistleblower Protection Act of 2022, we established the Zeria Group Whistleblower Protection Rules, put the necessary systems in place, and communicated them internally and to our subsidiaries.」

    In response to the amended Whistleblower Protection Act, the company established group whistleblower protection rules and proceeded with communicating them internally and to its subsidiaries.
  3. FY2019RestatedAnnual report

    「In addition to further strengthening our financial position, we will continue working to further enhance the reliability of our group management by strengthening the operation of internal controls in compliance with the Companies Act, the Financial Instruments and Exchange Act and other applicable laws.」

    The company continues to improve the reliability of group management through compliance with laws and regulations and stronger internal control operations.
  4. FY2017RestatedAnnual report

    「In addition to further strengthening our financial position, we will continue working to further enhance the reliability of our group management by strengthening the operation of internal controls in compliance with the Companies Act, the Financial Instruments and Exchange Act and other applicable laws.」

    The company continues to strengthen the operation of internal controls and its systems for managing subsidiaries and conducting internal audits.
  5. FY2016First statedAnnual report

    「We will continue working to further enhance the reliability of our group management by strengthening the operation of internal controls in compliance with the Companies Act, the Financial Instruments and Exchange Act and other applicable laws.」

    The disclosure describes systems including the dispatch of officers to subsidiaries, rules for managing affiliated companies and internal audits.
Moved together

"Further Strengthening of the Financial Position" moved the same way as this thread, in the same document, in 2 of its 5 moves.

222222★123456
  1. ★This thread
  2. 1Further Strengthening of the Financial Position2×
  3. 2Stable and Consistent Dividends and Strengthening Retained Earnings2×
  4. 3Recovery in Revenue, Operating Profit and Net Income2×
  5. 4Expansion of the European and Other Businesses through the Transfer of the Marketing Rights for Dificlir Tablets2×
  6. 5Strengthening the Foundation as a Global Company2×
  7. 6Growth of the Prescription Pharmaceutical Business Driven by Asacol, Acofide, and Entocort2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
Zeria Pharmaceutical's next results are scheduled for 2026-11-04. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.